Skip to main content

Table 1 Clinical and laboratory characteristics and empirical antimicrobial therapy of the patients

From: The effect of a rapid molecular blood test on the use of antibiotics for nosocomial sepsis: a randomized clinical trial

Variable Intervention group
(n = 100)
Control group
(n = 100)
Presumed infection site
 Primary bloodstream infection 38 (40.4%) 43 (47.8%)
 Non-ventilator associated pneumonia 20 (21.3%) 18 (20.0%)
 Ventilator-associated pneumonia 15 (16.0%) 13 (14.4%)
 Skin and soft tissue 6 (6.4%) 2 (2.2%)
 Urinary tract infection 6 (6.4%) 3 (3.3%)
 Intra-abdominal infection 1 (1.1%) 5 (5.6%)
 Endocarditis 2 (2.1%) 2 (2.2%)
 Surgical site infection 0 (0%) 2 (2.2%)
 Pleural empyema 2 (2.1%) 0 (0%)
 Other sites 2 (2.1%) 1 (1.1%)
 Unknown focus 2 (2.1%) 1 (1.1%)
Severe sepsis or septic shock 83 (88.3%) 81 (90.0%)
Renal replacement therapy during sepsis 37 (37.0%) 36 (36.0%)
SOFA score, median (IQR) 7 (4–10) 8 (5–10)
C-reactive protein (mg/dL), median (IQR) 154 (106–237) 168 (104–248)
Admission lactate (mmol/L), median (IQR) 2 (1.55–2.66) 2.2 (1.55–3)
Antimicrobial exposure on time of blood collection, n (%) 58 (58.0%) 51 (51.0%)
Previous multidrug resistance colonization, n (%) 28 (28.0%) 32 (32.0%)
Empirical antimicrobial therapy
 Glycopeptides 1 (1.1%) 0 (0%)
 Fluoroquinolones or 3rd-generation cephalosporins 6 (6.4%) 4 (4.4%)
 Piperacillin-tazobactan or cefepime or aminoglycosides 24 (25.5%) 25 (27.8%)
 Meropenem or polymyxin or tigecycline 63 (67.0%) 61 (67.8%)
Empirical MRSA coverage (glycopeptides, linezolid, and daptomycin) 93 (94.9%) 95 (95%)
Empirical Meropenem 65 (65%) 68 (68.7%)
Antimicrobial regimen
 Monotherapy 6 (6.2%) 5 (5%)
 2 antibiotics 70 (72.2%) 71 (71.0%)
 3 antibiotics 16 (16.5%) 20 (20.0%)
 ≥ 4 antibiotics 5 (5.2%) 4 (4.0%)
  1. SOFA Sequential Organ Failure Assessment, LOS length of stay, MRSA methicillin-resistant Staphylococcus aureus, IQR interquartile range